Digbi Health, a Mountain View, Calif.-based provider of a gut microbiome & genetic risk based precision care program, completed a $5.4m Series A funding.
The round, which brought total funding raised to date to $8.5m, was led by Accel, with participation from Wisdom LLP and seed backers Ocean Azul Partners and Seraph Venture.
The company intends to use the funds to continue to expand its business reach forging additional payer, employer and Third-party administrator (TPA) partnerships, along with its product offering, engineering, gut microbiome and data science teams in the US and India. In addition, Digbi Health will add to its existing clinical research partners – West Virginia University Medicine, UC Irvine Medical School, while investing in an FDA approval pathway for Software as a Medical Device (SaMD) targeting functional bowel disorder.
Founded in 2018 by CEO Ranjan Sinha, Digbi Health provides a clinically proven genetics and gut-microbiome based digital care program for managing obesity and associated inflammatory digestive, skin and cardiometabolic illnesses
For insurance payers, ACOs, the company offers a value-based, payer validated, personalized population health platform for obesity and polychronic inflammatory illnesses – digestive, skin and chronic pain.
For employers, Digbi Health offers a personalized digital care platform for a diverse workforce, whose disease risk varies significantly by gender and ethnicity because they are rooted in the person’s genetic and gut microbiome.